Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Trimodality Therapy for Prostate Cancer
Recruiting2 awardsPhase 2
Durham, North Carolina
This trial will enroll prostate cancer patients who have an unfavorable outlook. They will receive a combination of drugs, radiation, and androgen deprivation therapy. Afterward, they will have surgery to remove the prostate. The tissue will be analyzed and they will be monitored for 2 years to see if their cancer returns.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service